Daehan New Pharm Co Ltd
KOSDAQ:054670
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Daehan New Pharm Co Ltd
Income from Continuing Operations
Daehan New Pharm Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Daehan New Pharm Co Ltd
KOSDAQ:054670
|
Income from Continuing Operations
₩15.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
Yuhan Corp
KRX:000100
|
Income from Continuing Operations
₩185.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
4%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Income from Continuing Operations
₩253.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Income from Continuing Operations
₩187.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
61%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Income from Continuing Operations
₩12B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-4%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Income from Continuing Operations
₩20.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Daehan New Pharm Co Ltd
Glance View
Daehan New Pharm Co., Ltd. engages in the production of pharmaceuticals and animal health goods. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2002-02-26. The firm provides two categories of products: human pharmaceutical products and animal pharmaceutical products. Its human pharmaceutical products include analgesics, anti-inflammatory drugs, antipyretics, antibacterial, antidiabetics, antihistamines, antineoplastics, immunosuppressants, cardiovascular drugs, gastrointestinal drugs, muscle relaxants, antispasmodics and others. Its animal pharmaceutical products include antibacterial, coccidiostats, antihelmintics, probiotic, nutrients, metabolic stimulants, disinfectants, functional supplement feeds, liver tonics, antihelmintics and others for poultries, cattle, sheep, swine and fishes.
See Also
What is Daehan New Pharm Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
15.3B
KRW
Based on the financial report for Dec 31, 2025, Daehan New Pharm Co Ltd's Income from Continuing Operations amounts to 15.3B KRW.
What is Daehan New Pharm Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%
Over the last year, the Income from Continuing Operations growth was -1%. The average annual Income from Continuing Operations growth rates for Daehan New Pharm Co Ltd have been -14% over the past three years , and 14% over the past ten years .
